Currently, there are 45.64M common shares owned by the public and among those 43.12M shares have been available to trade.
The company’s stock has a 5-day price change of 0.38% and -2.03% over the past three months. ABEO shares are trading -4.85% year to date (YTD), with the 12-month market performance up to 66.14% higher. It has a 12-month low price of $3.37 and touched a high of $6.78 over the same period. ABEO has an average intraday trading volume of 594.44K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.36%, 3.89%, and -4.85% respectively.
Institutional ownership of Abeona Therapeutics Inc (NASDAQ: ABEO) shares accounts for 63.90% of the company’s 45.64M shares outstanding.
It has a market capitalization of $258.64M and a beta (3y monthly) value of 1.70. The earnings-per-share (ttm) stands at -$2.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.04% over the week and 9.19% over the month.
Earnings per share for the fiscal year are expected to increase by 95.35%, and 124.31% over the next financial year.
Looking at the support for the ABEO, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on March 05, 2025, with the firm’s price target at $16. H.C. Wainwright coverage for the Abeona Therapeutics Inc (ABEO) stock in a research note released on July 03, 2024 offered a Buy rating with a price target of $15. Stifel was of a view on May 30, 2024 that the stock is Buy, while Cantor Fitzgerald gave the stock Overweight rating on November 11, 2020, issuing a price target of $4. B. Riley FBR on their part issued Buy rating on September 18, 2020.
